ALBIREO PHARMA INC. overview

Bylvay (odevixibat) granted Priority Review by U.S. FDA ASSERT study demonstrated efficacy of Bylvay in pruritus, bile acids and sleep with a low drug-related diarrhea rate in Alagille patients Approval in second indication would more than double Bylvay market opportunity BOSTON, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare disease company developing novel bile acid modulators to treat pediatric and adult liver diseases, today announced that the U.S. Food and...

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Albireo Pharma, Inc. (NasdaqCM: ALBO) to Ipsen S.A. Under the terms of the proposed transaction, shareholders of Albireo will receive $42.00 in cash plus one contingent value right per share (CVR) (entitling its holder to deferred cash payments of $10.00 per CVR payable upon the U.S. Food and Drug Administration’s approval of Bylvay in...

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Albireo Pharma, Inc. (NasdaqCM: ALBO) to Ipsen S.A. Under the terms of the proposed transaction, shareholders of Albireo will receive $42.00 in cash plus one contingent value right per share (CVR) (entitling its holder to deferred cash payments of $10.00 per CVR payable upon the U.S. Food and Drug Administration’s approval of Bylvay in...

SHAREHOLDER ALERT: Weiss Law Investigates Albireo Pharma, Inc. PR Newswire NEW YORK, Jan. 9, 2023 NEW YORK , Jan. 9, 2023 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Albireo Pharma, Inc. ("Albireo" or the "Company") (NASDAQ: ALBO), in connection with the proposed acquisition of the Company by Ipsen S.A. (OTC: IPSEY) via tender offer. Under the terms of the merger agreement, the Company's shareholders will...

ALERT: The M&A Class Action Firm Announces the Investigation of Albireo Pharma, Inc. - ALBO PR Newswire NEW YORK, Jan. 9, 2023 NEW YORK , Jan. 9, 2023 /PRNewswire/ -- Juan Monteverde , founder and managing partner of the class action firm Monteverde & Associates PC (the "M&A Class Action Firm"), a national securities firm rated Top 50 in the 2018-2021 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City , is investigating Albireo Pharma,...

Shareholder Alert: Ademi LLP investigates whether Albireo Pharma, Inc. has obtained a Fair Price in its transaction with Ipsen PR Newswire MILWAUKEE, Jan. 9, 2023 MILWAUKEE , Jan. 9, 2023 /PRNewswire/ -- Ademi LLP is investigating Albireo (Nasdaq: ALBO) for possible breaches of fiduciary duty and other violations of law in its transaction with Ipsen. Click here to learn how to join the action https://www.ademilaw.com/case/albireo-pharma-inc or call Guri Ademi toll-free at 866-264-3995. There is...

Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Albireo Pharma, Inc. (NASDAQ: ALBO) to Ipsen is fair to Albireo shareholders. Per the terms of the proposed transaction, Ipsen would acquire Albireo for $42.00 per share in cash plus one contingent value right per share (CVR), entitling its holder to deferred cash payments of $10.00 per CVR payable upon the U.S. Food and Drug Administration’s approval of Bylvay in the Biliary Atresia indication by December 31,...

BOSTON, Dec. 20, 2022 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators to treat pediatric and adult liver diseases, today announced the grant to its newly appointed Chief Medical Officer, Paul D. Streck, M.D., of inducement restricted stock units to acquire 63,966 shares of Albireo’s common stock. The restricted stock units were granted as an inducement material to Dr. Streck’s acceptance of employment with Albireo in...